MedTrace Logo

Quality of Life and Health Economic Measurements in Allergic Patients Treated With Immunotherapy

NCT01486498 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 571

Last updated 2011-12-06

No results posted yet for this study

Summary

Grass pollen and house dust mites (HDM) are the most common allergens causing allergic rhino-conjunctivitis (RC) and/or asthma (A). Subcutaneous allergen specific immunotherapy (SCIT) reduces symptoms and use of medication. The purpose of SABAL is to assess the effect of SCIT on disease severity classifications in terms of number of days affected- and sick days on patients with grass pollen and/or HDM induced disease. These outcome measures will be gathered in one single measure: Quality Adjusted Life Years (QALY)

Conditions

Sponsors & Collaborators

  • Aalborg University

    lead OTHER

Principal Investigators

  • Karin D Petersen, PhD · Associate Professor

Eligibility

Min Age
16 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2005-11-30
Primary Completion
2009-11-30
Completion
2011-11-30

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01486498 on ClinicalTrials.gov